NeuroSense Therapeutics Ltd. (NRSNW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 23Sep 28Oct 2Oct 12Oct 15Oct 21Oct 27Nov 4

Key dataNov 4, 2026

Open$0.01

From 52W high−98.56%

Volume1754.00

Market cap$292123.00

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$0.01

From 52W high

−98.56%

Volume

1754.00

Market cap

$292123.00

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.0x

P/E (TTM)

—

RSI (14)

40.1

MomentumView details →

1D Return

+53.33%

YTD Return

−97.58%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−0.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

713.14%

ROA (TTM)

−1082.20%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+20.00%

EBITDA YoY

−43.61%

MomentumView details →

1D Return

+53.33%

YTD Return

−97.58%

1Y Return

−97.42%

RSI (14)

40.1

vs 50D SMA

−84.62%

vs 200D SMA

−95.88%

Capital & dividendView details →

Debt/Equity

−0.11x

Current Ratio

0.31x

Quick Ratio

0.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$2.06

EPS Surprise

47.18%

Beats (12Q)

3/12

Next Q EPS Est

−$2.38

Avg Surprise (4Q)

−34.53%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−11.13M

Op. CF (TTM)

−3.67M

Next earningsDec 2, 2026 →

Latest newsMore news →

Health Canada confirmed a March 2027 filing timeline for NeuroSense Therapeutics' PrimeC Canadian ALS submission, which will include new neurofilament light chain analysis.2d ago

NeuroSense Therapeutics Ltd. announced that it will present clinical and biomarker evidence from its NeuroSense Therapeutics Ltd. program at NEALS 2026 to inform PrimeC's Phase 3 development strategy.6d ago

Similar companies

SciSparc Ltd.SPRC NRx Pharmaceuticals, Inc.NRXPW Lyra Therapeutics, Inc.LYRA BriaCell Therapeutics Corp. WarrantBCTXZ Ainos, Inc.AIMDW CDT Equity Inc.CDT Find similar companies →

Latest newsMore news →

Health Canada confirmed a March 2027 filing timeline for NeuroSense Therapeutics' PrimeC Canadian ALS submission, which will include new neurofilament light chain analysis.2d ago NeuroSense Therapeutics Ltd. announced that it will present clinical and biomarker evidence from its NeuroSense Therapeutics Ltd. program at NEALS 2026 to inform PrimeC's Phase 3 development strategy.6d ago NeuroSense Therapeutics filed a U.S. patent application seeking protection for PrimeC use in traumatic brain injury, including concussion, blast-related brain injury and chronic traumatic encephalopathy.16d ago